| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/13/2001 | CA2409197A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells |
| 12/13/2001 | CA2381249A1 Methods and compositions for modulating oxidized ldl transport |
| 12/12/2001 | EP1162458A1 Methods and compositions for modulating oxidized LDL transport |
| 12/12/2001 | EP1162265A2 Human PEM as a target for fertility control and Alzheimer therapy |
| 12/12/2001 | EP1161954A1 Treatment of T cell mediated autoimmune disorders |
| 12/12/2001 | EP1161952A2 Human therapeutic uses of BPI protein products |
| 12/12/2001 | EP1161943A2 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds |
| 12/12/2001 | EP1161687A1 Grb14 and the insulin receptor and screening of novel medicines |
| 12/12/2001 | EP1161534A1 Differential expression of organellar gene products |
| 12/12/2001 | EP1161525A2 Methods and compositions for regulating memory consolidation |
| 12/12/2001 | EP1161448A1 49 human secreted proteins |
| 12/12/2001 | EP1161444A1 A novel inhibitor of programmed cell death |
| 12/12/2001 | EP1161442A2 Exocytosis pathway proteins and methods of use |
| 12/12/2001 | EP1161433A1 Tyrosine kinase inhibitors |
| 12/12/2001 | EP1161431A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 12/12/2001 | EP1161422A1 Amine derivatives as protease inhibitors |
| 12/12/2001 | EP1161415A2 N-cyanomethylamides as protease inhibitors |
| 12/12/2001 | EP1161279A1 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin |
| 12/12/2001 | EP1161266A1 Matriptase, a serine protease and its applications |
| 12/12/2001 | EP1161262A1 SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS |
| 12/12/2001 | EP1161261A1 Apoptosis inducing molecule ii and methods of use |
| 12/12/2001 | EP1161248A1 Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia |
| 12/12/2001 | EP1161242A1 Composition and method for treating diabetes |
| 12/12/2001 | EP1161238A1 Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist |
| 12/12/2001 | EP1161235A1 Combinations for the treatment of diseases involving angiogenesis |
| 12/12/2001 | EP1161226A1 Phosphocholine linked prodrug derivatives |
| 12/12/2001 | EP1161147A1 Peptide mimics useful for treating disease |
| 12/12/2001 | EP0888127B1 Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors |
| 12/12/2001 | EP0785788B1 Use of cck-b receptor antagonists for the treatment of sleep disorders |
| 12/12/2001 | EP0782456B1 Conjugate consisting of an active substance and a non-exogenous native protein |
| 12/12/2001 | EP0760665B1 Compositions containing 5htia and 5htid antagonists |
| 12/12/2001 | EP0732923B1 Pharmaceutical compositions containing HIV protease inhibitors |
| 12/12/2001 | EP0688213B1 Treatment of tumors with compounds having rxr retinoid receptor agonist activity |
| 12/12/2001 | CN1326509A MOraxella catarrhalis ABSB034 polypeptides and uses thereof |
| 12/12/2001 | CN1326361A Methods for detecting, preventing, and treating renal disorders by modulating, regulating and inhibiting connective tissue growth factor |
| 12/12/2001 | CN1326353A Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 12/12/2001 | CN1326351A Use of certain drugs for treating nerve root injury |
| 12/12/2001 | CN1326337A Drug delivery device, especially for delivery of progestins and estrogens |
| 12/12/2001 | CN1326335A Process for the manufacture of liquid filled capsules |
| 12/11/2001 | US6329566 Methods for the detection, treatment, and prevention of neurodegeneration |
| 12/11/2001 | US6329488 Silane copolymer coatings |
| 12/11/2001 | US6329428 Therapy of disease of lower urinary tract system by using organic acid salt of (2-(4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl)ethyl)-dimeth ylsulfonium |
| 12/11/2001 | US6329422 Enhancing, stimulating chloride transport in epithelial cells; flavone or isoflavone or a stereoisomer thereof. |
| 12/11/2001 | US6329416 Administering to female of child bearing age for 28 consecutive days: first phase dosage of progestational agent; second phase of antiprogesin compound, and third phase of placebo for contraception |
| 12/11/2001 | US6329404 Pharmaceutical composition |
| 12/11/2001 | US6329403 Insulin sensitizer selected from pioglitazone, troglitazone, rosiglitazone, 4-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy) benzyl)isoxazolidin-3,5-dione or salt, in combination with sibutramine or mazindol |
| 12/11/2001 | US6329401 Enhancement of sleep with a tachykinin antagonist |
| 12/11/2001 | US6329384 Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation |
| 12/11/2001 | US6329374 Non-systemic control of parasites |
| 12/11/2001 | US6329355 Method for inhibiting the growth of cancers |
| 12/11/2001 | US6329352 Method and composition for treating sleep apnea |
| 12/11/2001 | US6329350 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 12/11/2001 | US6329349 Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents |
| 12/11/2001 | US6329348 Method of inducing angiogenesis |
| 12/11/2001 | US6329343 Bioadhesive, pyruvate, antioxidant, fatty acids for injuries |
| 12/11/2001 | US6329339 Lactoferrin with glycyrrhizic acid as synergist |
| 12/11/2001 | US6329159 An antibody or antigen binding fragment which binds mammalian chemokine receptor and inhibits the binding of ligand to the receptor; therapy and diagnosis of inflammatory disease associated with mucosal tissues |
| 12/11/2001 | US6328966 Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| 12/11/2001 | US6328964 Method to treat multiple sclerosis with GP39-specific antibodies |
| 12/11/2001 | CA2215234C Composition containing amlodipine, or its salt and an ace inhibitor |
| 12/11/2001 | CA2141788C Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use |
| 12/08/2001 | CA2347316A1 Growth promoting pharmaceutical implant |
| 12/06/2001 | WO2001092892A2 Methods to identify compounds that modulate rage |
| 12/06/2001 | WO2001092891A2 Regulating lipid levels via the zmax1 or hbm gene |
| 12/06/2001 | WO2001092876A2 Method for identifying compounds for modulating the activity of a tumour suppressor protein |
| 12/06/2001 | WO2001092584A1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 12/06/2001 | WO2001092581A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 12/06/2001 | WO2001092578A2 Reagents and methods for identifying and modulating expression of genes regulated by retinoids |
| 12/06/2001 | WO2001092567A2 Novel target genes for diseases of the heart |
| 12/06/2001 | WO2001092528A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092526A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | WO2001092496A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | WO2001092492A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | WO2001092491A2 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | WO2001092490A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | WO2001092485A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE |
| 12/06/2001 | WO2001092474A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | WO2001092337A2 Soluble ctla4 mutant molecules and uses thereof |
| 12/06/2001 | WO2001092312A1 Peptide substrate identified by type bont/b botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 12/06/2001 | WO2001092306A2 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092274A2 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 12/06/2001 | WO2001092239A1 Biciclic cyclohexylamines and their use as nmda receptor antogonists |
| 12/06/2001 | WO2001091792A2 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network |
| 12/06/2001 | WO2001091789A2 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | WO2001091785A2 Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 12/06/2001 | WO2001091783A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 12/06/2001 | WO2001091778A2 Compositions for treating neck and shoulder discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091772A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091770A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091768A2 Compositions for treating brain disorders and enhancing brain function, containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091765A2 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 12/06/2001 | WO2001091764A2 Extracts from spermatophyte plants with immunomodulating activity |
| 12/06/2001 | WO2001091760A1 New use |
| 12/06/2001 | WO2001091752A1 Melanocortin receptor agonists |
| 12/06/2001 | WO2001091746A1 Method for treating alcohol intoxication and alcohol abuse |
| 12/06/2001 | WO2001091744A1 Methods of treating androgen deficiency in men using selective antiestrogens |
| 12/06/2001 | WO2001091741A2 Compositions containing hexitol and an antiproliferative agent |
| 12/06/2001 | WO2001091740A2 Compositions containing naphthaquinone and an antiproliferative agent |